Professor Mark Hatherill, Director of the South African Tuberculosis Vaccine Initiative, University of Cape Town, leads clinical trials of novel tuberculosis vaccines and studies of TB risk biomarkers. A trained pediatrician and critical care specialist, his research focuses on efficacy trials of vaccine candidates like M72/AS01E and BCG revaccination to prevent Mycobacterium tuberculosis infection and disease in infants, adolescents, and adults. He is passionate about advancing TB prevention strategies and training the next generation of clinical researchers. 

Professor Elisa Nemes, immunologist at the South African Tuberculosis Vaccine Initiative, University of Cape Town, is involved in clinical trials of new tuberculosis vaccines, development of immunodiagnostics and basic immunological studies. Her research focuses on identifying immune correlates of protection from Mycobacterium tuberculosis  infection and TB disease, which can facilitate development and assessment of new vaccines. She is passionate about sharing her knowledge with the next generation of scientists.